Practical considerations in anticonvulsant therapy--Part 2.
Epilepsy is, for many patients, a lifelong condition that requires treatment with powerful drugs whose doses must be carefully titrated to avoid both breakthrough seizures and toxicity. The medication regimens used to treat epilepsy are further complicated by the fact that most seizure medications are metabolized in the liver and have the potential for serious pharmacokinetic drug-drug interactions with many other medications. Successful management of epilepsy requires a high degree of cooperation among the patient, the pharmacist, and the treating physician. Such cooperation can ensure that the appropriate treatment and drug preparation are selected, compliance is maintained, and dangerous drug-drug interactions are avoided.
D000927:Anticonvulsants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D003363:Cost Control; D004827:Epilepsy / Q000188:drug therapy*; D005013:Ethosuximide / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D008991:Monitoring, Physiologic; D010349:Patient Compliance; D010353:Patient Education as Topic; D010595:Pharmacists; D010634:Phenobarbital / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D010672:Phenytoin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D011324:Primidone / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D012380:Role; D014635:Valproic Acid / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use
D000927:Anticonvulsants; D001569:Benzodiazepines; D011324:Primidone; D005013:Ethosuximide; D014635:Valproic Acid; D010672:Phenytoin; D010634:Phenobarbital